Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 26;15:10232. doi: 10.1038/s41467-024-54145-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 1 — Previous studies using bulk RNA seq analysis of TNBC patients have identified five molecular subtypes: luminal androgen receptor, mesenchymal, mesenchymal stem-like, basal-like, and immunomodulatory. These subtypes are associated with distinct tumor microenvironments, characterized by variations in the rate of tumor-infiltrating lymphocytes, spatial immune organization (TIME classification), the presence or absence of tertiary lymphoid structures, and different types of cancer-associated fibroblasts. Figure 1 was partly generated using Servier Medical Art, provided by Servier (https://smart.servier.com/), licensed under Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). BL basal-like, CAF cancer-associated fibroblast, detox-iCAF detoxification pathway inflammatory cancer-associated fibroblast S1, ecm-myCAF extracellular matrix myofibroblastic cancer-associated fibroblast S1, DC dendritic cell, FI full inflamed, iCAF inflammatory cancer-associated fibroblast S1, ID immune desert, IFNγ-iCAF interferon gamma signaling pathway cancer-associated fibroblast S1, IL-iCAF IL pathway inflammatory cancer-associated fibroblast S1, IM immunomodulatory, LAR luminal androgen receptor, M mesenchymal, MR margin restricted, MSL mesenchymal stem-like, myCAF myofibroblastic cancer-associated fibroblast, SR stroma restricted, TGFβ-myCAF TGFbeta signaling pathway myofibroblastic cancer-associated fibroblast S1, TILs tumor-infiltrating lymphocytes, TIME Tumor Immune Micro-Environment, TLS tertiary lymphoid structure, wound-myCAF wound healing myofibroblastic cancer-associated fibroblast S1.